Author Archives: Mary Chapman

In Potential $100M Deal, Medexus Acquires Ixinity for Hemophilia B

In an agreement expected to exceed $100 million, Medexus Pharmaceuticals has bought global commercial rights to Ixinity, an approved recombinant factor IX therapy for hemophilia B previously marketed by Aptevo Therapeutics. Sale terms include an upfront $30 million payment, plus up to $11 million in prospective…

Audaire Health and AscellaHealth Partner to Promote Hemophilia Management Program

AscellaHealth and Audaire Health together are offering on a hemophilia management program that aims to containing prescription costs and help patients better manage their treatment needs. The program leverages AscellaHealth’s network of specialty pharmacy partners and Audaire’s healthcare technology to offer pharmacy network design, therapy utilization management, and clinical…

Patients, Supporters Worldwide Recognizing Rare Disease Day 2020

An abundance of events are afoot around the world to mark Rare Disease Day 2020 on Feb. 29. The activities are focused on heightening awareness about rare diseases and the hundreds of millions of individuals they are thought to affect. Patients, caregivers, and advocates worldwide will sport denim ribbons…